Terrestrial Bio Clinches $50 Million Series C Funding
Terrestrial Bio, a biotechnology firm based in Boston, Massachusetts, has successfully raised $50 million in a Series C funding round. The company is innovating the delivery of next-generation therapies by developing a microarray patch platform, starting with GLP-1 treatments. The funding round was spearheaded by RA Capital, with additional investments from Engine Ventures, GHIC, and SiteGround.
Leadership and Strategic Direction
The executive team at Terrestrial Bio comprises co-founders Kathryn Kosuda, who serves as Chief Scientific Officer, and Livio Valenti, the Senior Vice President of Operations. Rachel Sha is leading the company as CEO. Under their guidance, Terrestrial Bio has rebranded from its previous identity, Vaxess Technologies, to better align with its focus on revolutionary therapeutic delivery methods.
Innovative Microarray Patch Platform
Terrestrial Bio's microarray patch technology is designed to simplify and improve the administration of therapeutic treatments. This platform enables patients to self-administer treatments using a patch that works similarly to an adhesive bandage. The patch is equipped with bioactive tips that dissolve quickly upon application, releasing the therapeutic compounds into the skin without the need for traditional needles or refrigeration. This approach is not only more convenient but also enhances patient adherence and experience.
A recent study focusing on GLP-1 treatments indicated that participants overwhelmingly preferred the patch applicator over traditional injection methods, suggesting a favorable shift in patient experience.
Utilization of Funds
With the new capital from the Series C round, Terrestrial Bio plans to establish a new headquarters in Boston and expand its manufacturing capabilities. The company has signed a lease for a 40,000-square-foot facility in Boston’s Allston Labworks. This facility is set to support the scaled production of microarray patches and is expected to incorporate advanced technologies such as automation, robotics, and computer vision systems. Construction of the facility is slated to begin in 2026.
Future Plans and Market Impact
By advancing their microarray patch platform, Terrestrial Bio aims to make therapeutic treatments more accessible and user-friendly. The company's efforts in improving the delivery mechanisms for therapies hold the potential to significantly impact patient care and adherence, particularly for GLP-1 treatments. With demonstrated proof of concept in clinical settings, Terrestrial Bio is well-positioned to continue its development of next-generation therapies.
This funding marks a critical step for Terrestrial Bio as it moves towards late-stage clinical development and early commercial entry, potentially transforming how therapies are administered and experienced by patients globally.